SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TARS

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$73.01-$4.66 (-6.00%)
 
Market cap
$3.60B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 16, 2020
Market Cap$3.60B-8.3%
Revenue (ttm)$682.20M+86.3%
Net Income-$702.23M-765.3%
EPS-$15.19-652.0%
Shares Out49.31M
PE Ration/a
Forward PE164.03
Dividendn/a
Ex-Dividend Daten/a
Volume706,767
Open$77.09
Previous Close$77.67
Day's Range$72.74 - $78.11
52-Week Range$53.89 - $91.53
Beta0.54
AnalystsBuy
Price Target$103.43(+41.67%)
Earnings DateFeb 22, 2027

About TARS

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Address
15440 Laguna Canyon Road, Irvine, CA, 92618, US
Market Cap
3.60 billion
Employees
370
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$8.45M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $102.75 (+32.3%)

3 firms rating TARS in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From TARS’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-6.00%
5 Days
-10.25%
1 Month
+3.56%
6 Months
+15.01%
1 Year
-8.35%

$TARS stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TARS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TARS's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TARS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

TARS Revenue by Segment

$272.06MTotal
Product sales, net$194.57M71.52%
Selling and marketing$77.50M28.48%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New TARS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TARS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in TARS

FBTFirst Trust NYSE Arca Biotechnology Index Fund$98.60M
IWMiShares Russell 2000 ETF$85.28M
VTIVanguard Morningstar Total Stock Market ETF$83.44M
VXFVanguard Extended Market ETF$32.82M
IWOiShares Russell 2000 Growth ETF$30.72M
IBBiShares Biotechnology ETF$28.19M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from TARS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
21
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 4
0255075100Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 25.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 4Sep 19Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

FBTFirst Trust NYSE Arca Biotechnology Index Fund3.58%
PJPInvesco Pharmaceuticals ETF3.24%
SBIOALPS Medical Breakthroughs ETF2.21%
XPHState Street SPDR S&P Pharmaceuticals ETF1.85%
BBPVirtus Biotech ETF1.59%
HAPSHarbor Human Capital Factor US Small Cap ETF1.34%
IHEiShares U.S. Pharmaceuticals ETF0.60%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.53%
FSEGFidelity Enhanced Small Cap Growth ETF0.37%
HELXFranklin Genomic Advancements ETF0.31%
PJSMPGIM Jennison Small-Mid Cap Core Equity ETF0.29%
MMSCFirst Trust Multi-Manager Small Cap Opportunities ETF0.28%

Weight is the stock’s share of each fund’s holdings.